Literature DB >> 27557665

The microRNA signatures: aberrantly expressed microRNAs in head and neck squamous cell carcinoma.

Keiichi Koshizuka1,2, Toyoyuki Hanazawa2, Ichiro Fukumoto1,2, Naoko Kikkawa2, Yoshitaka Okamoto2, Naohiko Seki1.   

Abstract

microRNAs (miRNAs) are responsible for fine tuning the normal expression of RNA networks in human cells. Accumulating studies have demonstrated that abnormally expressed miRNAs have pivotal roles in the development of head and neck squamous cell carcinoma (HNSCC). Specifically, expression signatures of miRNAs in HNSCC have revealed dysregulated production of miRNAs and the resultant abnormal production of mRNAs and proteins. In this review, we discuss current findings regarding aberrantly expressed miRNAs and their contribution to HNSCC molecular pathogenesis.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27557665     DOI： 10.1038/jhg.2016.105

Source DB:  PubMed          Journal:  J Hum Genet        ISSN： 1434-5161            Impact factor:   3.172


  121 in total

1.  Tumor suppressive microRNA-375 regulates oncogene AEG-1/MTDH in head and neck squamous cell carcinoma (HNSCC).

Authors:  Nijiro Nohata; Toyoyuki Hanazawa; Naoko Kikkawa; Muradil Mutallip; Daiju Sakurai; Lisa Fujimura; Kazumori Kawakami; Takeshi Chiyomaru; Hirofumi Yoshino; Hideki Enokida; Masayuki Nakagawa; Yoshitaka Okamoto; Naohiko Seki
Journal:  J Hum Genet       Date:  2011-07-14       Impact factor: 3.172

2.  MiR-139 targets CXCR4 and inhibits the proliferation and metastasis of laryngeal squamous carcinoma cells.

Authors:  Hua-Nan Luo; Zheng-Hui Wang; Ying Sheng; Qing Zhang; Jing Yan; Jin Hou; Kang Zhu; Ying Cheng; Ying-Long Xu; Xiang-Hong Zhang; Min Xu; Xiao-Yong Ren
Journal:  Med Oncol       Date:  2013-12-07       Impact factor: 3.064

Review 3.  Tumor-suppressive microRNA silenced by tumor-specific DNA hypermethylation in cancer cells.

Authors:  Ken-ichi Kozaki; Johji Inazawa
Journal:  Cancer Sci       Date:  2012-03-13       Impact factor: 6.716

4.  The tumor-suppressive microRNA-143/145 cluster inhibits cell migration and invasion by targeting GOLM1 in prostate cancer.

Authors:  Satoko Kojima; Hideki Enokida; Hirofumi Yoshino; Toshihiko Itesako; Takeshi Chiyomaru; Takashi Kinoshita; Miki Fuse; Rika Nishikawa; Yusuke Goto; Yukio Naya; Masayuki Nakagawa; Naohiko Seki
Journal:  J Hum Genet       Date:  2013-11-28       Impact factor: 3.172

5.  Specific microRNAs are downregulated in human thyroid anaplastic carcinomas.

Authors:  R Visone; P Pallante; A Vecchione; R Cirombella; M Ferracin; A Ferraro; S Volinia; S Coluzzi; V Leone; E Borbone; C-G Liu; F Petrocca; G Troncone; G A Calin; A Scarpa; C Colato; G Tallini; M Santoro; C M Croce; A Fusco
Journal:  Oncogene       Date:  2007-06-11       Impact factor: 9.867

6.  miR-375 suppresses IGF1R expression and contributes to inhibition of cell progression in laryngeal squamous cell carcinoma.

Authors:  Jie Luo; Jianhui Wu; Zenghong Li; Hao Qin; Bin Wang; Thian-Sze Wong; Weiqiang Yang; Qing-Ling Fu; Wenbin Lei
Journal:  Biomed Res Int       Date:  2014-08-12       Impact factor: 3.411

7.  Regulation of the collagen cross-linking enzymes LOXL2 and PLOD2 by tumor-suppressive microRNA-26a/b in renal cell carcinoma.

Authors:  Akira Kurozumi; Mayuko Kato; Yusuke Goto; Ryosuke Matsushita; Rika Nishikawa; Atsushi Okato; Ichiro Fukumoto; Tomohiko Ichikawa; Naohiko Seki
Journal:  Int J Oncol       Date:  2016-03-15       Impact factor: 5.650

8.  Circulating small non-coding RNA signature in head and neck squamous cell carcinoma.

Authors:  Berta Victoria Martinez; Joseph M Dhahbi; Yury O Nunez Lopez; Katarzyna Lamperska; Paweł Golusinski; Lukasz Luczewski; Tomasz Kolenda; Hani Atamna; Stephen R Spindler; Wojciech Golusinski; Michal M Masternak
Journal:  Oncotarget       Date:  2015-08-07

9.  Different miRNA signatures of oral and pharyngeal squamous cell carcinomas: a prospective translational study.

Authors:  C B Lajer; F C Nielsen; L Friis-Hansen; B Norrild; R Borup; E Garnæs; M Rossing; L Specht; M H Therkildsen; B Nauntofte; S Dabelsteen; C von Buchwald
Journal:  Br J Cancer       Date:  2011-02-15       Impact factor: 7.640

10.  Tumor-suppressive microRNA-29 family inhibits cancer cell migration and invasion directly targeting LOXL2 in lung squamous cell carcinoma.

Authors:  Keiko Mizuno; Naohiko Seki; Hiroko Mataki; Ryosuke Matsushita; Kazuto Kamikawaji; Tomohiro Kumamoto; Koichi Takagi; Yusuke Goto; Rika Nishikawa; Mayuko Kato; Hideki Enokida; Masayuki Nakagawa; Hiromasa Inoue
Journal:  Int J Oncol       Date:  2015-12-14       Impact factor: 5.650
View more
  24 in total

1.  MiR-501-5p acts as an energetic regulator in head and neck squamous cell carcinoma cells growth and aggressiveness via reducing CLCA4.

Authors:  Bo Li; Yuan-Pei Jiang; Jie Zhu; Lei Meng
Journal:  Mol Biol Rep       Date:  2020-02-19       Impact factor: 2.316

Review 2.  HPV epigenetic mechanisms related to Oropharyngeal and Cervix cancers.

Authors:  Marina Di Domenico; Giancarlo Giovane; Soumaya Kouidhi; Rosamaria Iorio; Maurizio Romano; Francesco De Francesco; Antonia Feola; Camilla Siciliano; Luigi Califano; Antonio Giordano
Journal:  Cancer Biol Ther       Date:  2018-05-14       Impact factor: 4.742

3.  Dual strands of the miR-223 duplex (miR-223-5p and miR-223-3p) inhibit cancer cell aggressiveness: targeted genes are involved in bladder cancer pathogenesis.

Authors:  Sho Sugawara; Yasutaka Yamada; Takayuki Arai; Atsushi Okato; Tetsuya Idichi; Mayuko Kato; Keiichi Koshizuka; Tomohiko Ichikawa; Naohiko Seki
Journal:  J Hum Genet       Date:  2018-03-14       Impact factor: 3.172

4.  Regulation of HMGB3 by antitumor miR-205-5p inhibits cancer cell aggressiveness and is involved in prostate cancer pathogenesis.

Authors:  Yasutaka Yamada; Rika Nishikawa; Mayuko Kato; Atsushi Okato; Takayuki Arai; Satoko Kojima; Kazuto Yamazaki; Yukio Naya; Tomohiko Ichikawa; Naohiko Seki
Journal:  J Hum Genet       Date:  2017-12-01       Impact factor: 3.172

5.  Characteristic miRNA expression signature and random forest survival analysis identify potential cancer-driving miRNAs in a broad range of head and neck squamous cell carcinoma subtypes.

Authors:  Yury O Nunez Lopez; Berta Victoria; Pawel Golusinski; Wojciech Golusinski; Michal M Masternak
Journal:  Rep Pract Oncol Radiother       Date:  2017-11-20

6.  Annexin A1 down-regulation in head and neck squamous cell carcinoma is mediated via transcriptional control with direct involvement of miR-196a/b.

Authors:  Saúl Álvarez-Teijeiro; Sofía T Menéndez; M Ángeles Villaronga; Emma Pena-Alonso; Juan P Rodrigo; Reginald O Morgan; Rocío Granda-Díaz; Cecilia Salom; M Pilar Fernandez; Juana M García-Pedrero
Journal:  Sci Rep       Date:  2017-07-28       Impact factor: 4.379

7.  Integrative Analysis of miRNAs Identifies Clinically Relevant Epithelial and Stromal Subtypes of Head and Neck Squamous Cell Carcinoma.

Authors:  Jeremiah Holt; Vonn Walter; Xiaoying Yin; David Marron; Matthew D Wilkerson; Hyo Young Choi; Xiaobei Zhao; Heejoon Jo; David Neil Hayes; Yoon Ho Ko
Journal:  Clin Cancer Res       Date:  2020-11-04       Impact factor: 13.801

8.  The microRNA expression signature of pancreatic ductal adenocarcinoma by RNA sequencing: anti-tumour functions of the microRNA-216 cluster.

Authors:  Keiichi Yonemori; Naohiko Seki; Tetsuya Idichi; Hiroshi Kurahara; Yusaku Osako; Keiichi Koshizuka; Takayuki Arai; Atsushi Okato; Yoshiaki Kita; Takaaki Arigami; Yuko Mataki; Yuko Kijima; Kosei Maemura; Shoji Natsugoe
Journal:  Oncotarget       Date:  2017-07-26

9.  Integrated miRNA-mRNA spatial signature for oral squamous cell carcinoma: a prospective profiling study of Narrow Band Imaging guided resection.

Authors:  Camile S Farah; Simon A Fox; Andrew J Dalley
Journal:  Sci Rep       Date:  2018-01-16       Impact factor: 4.379

10.  Impact of novel oncogenic pathways regulated by antitumor miR-451a in renal cell carcinoma.

Authors:  Yasutaka Yamada; Takayuki Arai; Sho Sugawara; Atsushi Okato; Mayuko Kato; Satoko Kojima; Kazuto Yamazaki; Yukio Naya; Tomohiko Ichikawa; Naohiko Seki
Journal:  Cancer Sci       Date:  2018-03-09       Impact factor: 6.716
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.